Familial Mediterranean fever

Lore & Background

Familial Mediterranean fever is characterized by recurrent, self-limiting attacks of fever and painful inflammation, typically beginning before age 18 in 90% of patients. Attacks develop over two to four hours and last from six hours to five days. The most common presentations include abdominal attacks (95% of patients) mimicking peritonitis or appendicitis, joint attacks (75% of patients) affecting large leg joints, and chest attacks (40% of patients) involving pleuritis. Scrotal attacks, myalgia, and erysipeloid rashes occur less frequently. The Tel-Hashomer clinical criteria are widely used for diagnosis, though their reported sensitivity and specificity vary across studies.

Reader's Guide

Familial Mediterranean fever is significant as a prototypical autoinflammatory disorder, demonstrating how gain-of-function mutations in the MEFV gene lead to excessive pyrin inflammasome activity and overproduction of interleukin-1β. Its legacy includes the use of colchicine as a mainstay treatment, which reduces attack frequency and delays amyloidosis, though 5–10% of cases are colchicine-resistant and may require anakinra or canakinumab. The disorder highlights the importance of genetic testing for mutations in exons 2, 3, 5, and 10, which detects 97% of known mutations. Complications include AA-amyloidosis with kidney failure and increased risk of vasculitis-related diseases. The condition remains a model for understanding inflammasome biology and targeted anti-IL-1 therapy.

Did You Know?

• Ninety percent of all patients have their first attack before they are eighteen years old.
• The MEFV gene is located on the short arm of chromosome 16 (16p13).
• Colchicine, a drug otherwise mainly used in gout, decreases attack frequency in FMF patients.
• The metaraminol provocative test is not a standard diagnostic test for FMF in current medical practice.

Genetic Architecture and Population Distribution

Familial Mediterranean fever traces its origin to the MEFV gene, situated on the short arm of chromosome 16 at position 16p13. This gene produces a 781-amino-acid protein known as pyrin, also referred to as marenostrin. While the condition can theoretically affect any ethnic group, it clusters most heavily among populations with Mediterranean heritage—Levantines, Maghrebis, Sephardic and Mizrahi Jews, Assyrians, Armenians, Azerbaijanis, Druze, Kurds, Greeks, Turks, and Italians. Pathogenic variants concentrate primarily in exons 2, 3, 5, and 10 of the gene. A single mutated copy is generally insufficient to produce disease; the genetic threshold typically requires two defective alleles, inherited one from each parent or as two copies of the same variant. Yet a small subset of clinically confirmed patients carries only one mutation. Paradoxically, many individuals who meet the two-mutation genetic criterion never develop symptoms, and whether modifier genes or environmental triggers explain this gap remains unresolved in the literature.

Spectrum of Clinical Attacks

FMF manifests through seven distinct attack types, and the vast majority of patients—roughly ninety percent—experience their first episode before turning eighteen. Each episode builds over two to four hours and persists anywhere from six hours to five days, with fever accompanying most presentations. Abdominal crises dominate the clinical picture, affecting ninety-five percent of patients; they produce diffuse peritoneal inflammation with signs mimicking appendicitis, sometimes prompting unnecessary surgical exploration. Joint involvement, seen in three-quarters of patients, typically strikes a single large joint in the lower extremities. Chest attacks, present in about forty percent, involve pleuritis that impairs breathing or lying flat, while pericarditis remains uncommon. Scrotal inflammation of the tunica vaginalis is infrequent but can be misread as testicular torsion. Myalgia and erysipeloid skin rashes on the legs—each capable of mimicking cellulitis—appear rarely in isolation. Incomplete presentations, featuring localized tenderness with normal laboratory values, have also been documented.

Molecular Pathophysiology and the Pyrin Inflammasome

At the molecular level, pyrin normally functions as a regulatory node in the innate immune system. In healthy tissue, it binds the adaptor protein ASC together with the proform of caspase-1, assembling multiprotein complexes called inflammasomes in response to bacterial enterotoxins. This cascade ultimately drives processing and release of pro-inflammatory cytokines including interleukin-18 and IL-1β. In FMF, gain-of-function mutations render pyrin hyperactive, amplifying inflammasome formation. Under basal conditions, pyrin is held inactive by a 14.3.3-family chaperone anchored through phosphorylated serine residues; dephosphorylation is a prerequisite for activation. In healthy individuals, dephosphorylation alone does not trigger the inflammasome, but in FMF patients it is sufficient—implying a second, independent regulatory layer is defective. This missing brake likely resides in the B30.2 domain within exon 10, where most pathogenic mutations cluster, and probably involves failed interaction with microtubules, a hypothesis supported by colchicine's therapeutic efficacy. The precise trigger for individual attacks and the organ-specificity of symptoms remain incompletely understood, though steroid catabolites such as pregnanolone and etiocholanolone have been shown to activate the pyrin inflammasome.

Complications, Diagnostic Criteria, and Nomenclature

Beyond the acute episodes, the most feared long-term consequence is AA-amyloidosis, which can progress to renal failure even in the absence of overt crises. During attacks, the body generates AA amyloid protein in very large quantities, with continued low-level production between episodes; the protein accumulates predominantly in the kidney, heart, spleen, gastrointestinal tract, and thyroid. An elevated risk of vasculitis-related conditions—including Henoch-Schönlein purpura, polyarteritis nodosa, and Behçet's disease—along with spondylarthropathy, prolonged joint arthritis, and persistent myalgia, has also been noted. For diagnosis, the Tel-Hashomer clinical criteria enjoy over ninety-five percent sensitivity and ninety-seven percent specificity. A typical attack requires at least three recurrent episodes, rectal temperature of thirty-eight degrees Celsius or higher, painful inflammation, and a duration between twelve and seventy-two hours. Incomplete attacks must still be recurrent but may deviate in temperature, duration (bounded by six hours to seven days), localization, absence of peritonitis signs, or atypical joint involvement. The disorder has accumulated numerous historical names, from periodic peritonitis and Reimann syndrome to Siegal-Cattan-Mamou disease and Wolff periodic disease.

Gallery